Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.

Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM.

Hepatology. 2008 Dec;48(6):1769-78. doi: 10.1002/hep.22549.

2.

Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.

Mo H, Yang C, Wang K, Wang Y, Huang M, Murray B, Qi X, Sun SC, Deshpande M, Rhodes G, Miller MD.

J Viral Hepat. 2011 May;18(5):338-48. doi: 10.1111/j.1365-2893.2010.01314.x.

PMID:
20456634
3.

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.

López-Labrador FX, Moya A, Gonzàlez-Candelas F.

Antivir Ther. 2008;13(4):481-94.

PMID:
18672527
4.

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.

Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C.

Hepatology. 2009 Dec;50(6):1709-18. doi: 10.1002/hep.23192.

PMID:
19787809
5.

[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].

Tornai I.

Orv Hetil. 2015 May 24;156(21):849-54. doi: 10.1556/650.2015.30180. Review. Hungarian.

PMID:
26038992
6.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

8.

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.

Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P.

J Clin Microbiol. 2015 Jul;53(7):2195-202. doi: 10.1128/JCM.03633-14. Epub 2015 Apr 29.

9.

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.

Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.

J Med Virol. 2014 Nov;86(11):1868-76. doi: 10.1002/jmv.24016. Epub 2014 Jul 23.

PMID:
25052594
10.

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C; ANRS AC11 HCV Group.

Antivir Ther. 2011;16(7):1093-102. doi: 10.3851/IMP1900.

PMID:
22024525
11.

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.

Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Böcher WO, Datsenko Y, Steinmann G, Scherer J, Stern JO, Kukolj G.

Antimicrob Agents Chemother. 2014;58(2):698-705. doi: 10.1128/AAC.01976-13. Epub 2013 Nov 11.

12.

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.

Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, Guardia J, Quer J.

Virology. 2008 Jan 20;370(2):237-45. Epub 2007 Nov 19.

13.

[Telaprevir resistance].

Poveda E, García F.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Review. Spanish.

PMID:
24063900
14.

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.

Lawitz EJ, Hill JM, Marbury T, Demicco MP, Delaney W, Yang J, Moorehead L, Mathias A, Mo H, McHutchison JG, Rodriguez-Torres M, Gordon SC.

Antivir Ther. 2013;18(3):311-9. doi: 10.3851/IMP2415. Epub 2012 Oct 9.

PMID:
23047118
15.

Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients.

Zabek P, Opoka-Kegler J, Baka M, Dyda T, Stańczak GP, Stańczak JJ.

Przegl Epidemiol. 2013;67(3):411-3, 521-3. English, Polish.

16.

Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.

Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR.

Antivir Ther. 2015;20(3):271-80. doi: 10.3851/IMP2850. Epub 2014 Sep 15.

PMID:
25222708
17.

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD.

J Biol Chem. 2005 Nov 4;280(44):36784-91. Epub 2005 Aug 8.

18.

Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.

Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J.

Gastroenterology. 2014 Mar;146(3):812-821.e4. doi: 10.1053/j.gastro.2013.11.009. Epub 2013 Nov 18.

PMID:
24262279
19.

The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.

Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA.

PLoS Pathog. 2012;8(7):e1002832. doi: 10.1371/journal.ppat.1002832. Epub 2012 Jul 26.

20.

A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.

Ivanisenko NV, Mishchenko EL, Akberdin IR, Demenkov PS, Likhoshvai VA, Kozlov KN, Todorov DI, Gursky VV, Samsonova MG, Samsonov AM, Clausznitzer D, Kaderali L, Kolchanov NA, Ivanisenko VA.

PLoS One. 2014 Mar 18;9(3):e91502. doi: 10.1371/journal.pone.0091502. eCollection 2014.

Supplemental Content

Support Center